Next Article in Journal
From the Identification to the Dissection of the Physiological Role of the Mitochondrial Calcium Uniporter: An Ongoing Story
Next Article in Special Issue
Myocardial and Arrhythmic Spectrum of Neuromuscular Disorders in Children
Previous Article in Journal
Harnessing the Physiological Functions of Cellular Prion Protein in the Kidneys: Applications for Treating Renal Diseases
Previous Article in Special Issue
Troponin T Mutation as a Cause of Left Ventricular Systolic Dysfunction in a Young Patient with Previous Surgical Correction of Aortic Coarctation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 11
Issue 6
10.3390/biom11060785
Review Report
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors

Biomolecules 2021, 11(6), 785; https://doi.org/10.3390/biom11060785
by Roberta Esposito 1,2,*, Teresa Fedele 1, Silvia Orefice 1, Vittoria Cuomo 1, Maria Prastaro 3, Mario Enrico Canonico 3, Federica Ilardi 2,3, Francesco De Stefano 4, Ludovica Fiorillo 1, Ciro Santoro 3 and Giovanni Esposito 3
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Biomolecules 2021, 11(6), 785; https://doi.org/10.3390/biom11060785
Submission received: 18 April 2021 / Revised: 15 May 2021 / Accepted: 17 May 2021 / Published: 22 May 2021
(This article belongs to the Special Issue 10th Anniversary of Biomolecules—Recent Advances in Cardiomyopathy)

Round 1

Reviewer 1 Report

When it comes to immune check point inhibitors, it would be good to cover the recent progress on PDL1 inhibitors. As currently PDL1 inhibitors are the main class of antibodies that are in clinical trails and are in use also. Also, the authors mostly covered the areas related to myocardia, but ICIs have also been used to treat cancers and also to overcome PDx resistance. Some important immunological areas covering ICIs are missing in this review.

Author Response

Thank you for the great suggestions. We tried to follow them.

Reviewer 2 Report

This is a very interesting and well written review by Esposito et al, which sheds light on the topic of Immune checkpoint inhibitor mediated myocarditis. I would suggest some minor corrections.

 

  1. On Line 89-94 i would suggest enlarging the discussion on this interesting study. This is especially important for epidemiological insights.
  2. While echocardiography as a baseline investigation is pointed out on Figure 3, it is not mentioned in Chapter 2. It is essential to initially evaluate baseline cardiac function in patients at risk for developing myocarditis due to ICI.

(Also discussed : Oncotarget . 2017 Nov 21;8(63):106165-106166.  doi: 10.18632/oncotarget.22579.  )

  1. On page 6 you discuss Lake Louis criteria from 2009, which were updated in 2018. Please add reference and update lake louis criteria in the text (J Am Coll Cardiol . 2018 Dec 18;72(24):3158-3176. doi: 10.1016/j.jacc.2018.09.072.)
  2. On page 6 Lines 257-258 false negative results of EMB are discussed. Here a reference would be helpful. I would consider discussing explicit indications for EMB. (J Am Coll Cardiol 2018 Dec 18;72(24):3158-3176. doi: 10.1016/j.jacc.2018.09.072.)

 

 

Author Response

Thank you for your suggestions, the answers are attached.

Author Response File: Author Response.pdf

Back to TopTop